Tirzepatide Cost and Access: Real Numbers and How to Pay Less

By the FormBlends Editorial Team. Medically reviewed by Dr. Sarah Chen, MD.

Last March, a woman named Rachel in Phoenix told me she'd lost 31 pounds in four months on tirzepatide. Then her employer switched insurance carriers. Her new plan excluded weight management drugs entirely. The pharmacy quoted her $1,047 for a four-week supply of Zepbound. "I sat in my car in the CVS parking lot and cried," she said. "Not because of the weight. Because I knew I couldn't afford to keep losing it."

Rachel's story is not unusual. It is, depressingly, the norm. The single most common reason patients fail on tirzepatide isn't nausea or injection anxiety. It's the price tag. Brand Mounjaro and Zepbound list at roughly $1,069 per month at retail, and even patients with insurance often face copays that make a full year of therapy financially impossible.

This page lays out the real cost landscape: list prices, GoodRx prices, manufacturer programs, insurance realities, and what compounded tirzepatide actually costs through licensed pharmacies. Think of it as a buyer's guide. The goal is to help you understand the trade-offs at each price point so you can make a decision that doesn't blow up your finances six months in.

For broader context on tirzepatide as a therapy, see the main Compounded Tirzepatide Complete Guide.

Important: Compounded tirzepatide is not FDA-approved. FormBlends is not a medical practice. We do not prescribe or dispense medication. Cost figures below are estimates based on publicly available data as of the publication date and will change.

What Brand Tirzepatide Actually Costs at the Register

Mounjaro (tirzepatide for type 2 diabetes) and Zepbound (tirzepatide for chronic weight management) are both manufactured by Eli Lilly. Same molecule. Same price. Approximately $1,069 per month for all dose strengths, from 2.5 mg to 15 mg.

A four-week supply is four single-dose pens. The list price doesn't budge whether you're titrating at the lowest dose or maxed out.

Without insurance, retail pharmacies charge within spitting distance of list. CVS, Walgreens, and supermarket pharmacies are usually within 5 percent. Costco and warehouse pharmacies sometimes shave 10 to 15 percent. That's the extent of the good news.

GoodRx Barely Moves the Needle

Here's the thing about GoodRx and tirzepatide: the savings are almost embarrassingly small.

GoodRx and similar discount card programs negotiate cash-pay prices with retail pharmacies. For Mounjaro and Zepbound in 2025, GoodRx prices ranged from approximately $980 to $1,050 per month depending on location and pharmacy. That's a 3 to 10 percent discount. Compare that to older generic drugs where GoodRx routinely produces 50 to 90 percent savings, and the disappointment is obvious.

The reason is simple. Tirzepatide is a single-source brand drug. No generic exists. Pharmacies have almost no margin to discount because their own acquisition cost is already sky-high. GoodRx can't squeeze water from a stone.

For more detail on cash-pay pricing strategies, see our supporting article on tirzepatide cash prices.

Manufacturer Savings Programs: The Fine Print Matters

Eli Lilly runs savings card programs for both Mounjaro and Zepbound. Eligibility and benefit levels change frequently (sometimes quarterly), so always verify current terms on Lilly's official website before planning around any specific number.

As of late 2025, the structure looked roughly like this:

• Zepbound Savings Card (commercial insurance): Reduces copay to as low as $25 per month for eligible patients with commercial insurance that covers Zepbound. Capped per fill and per year.
• Zepbound Savings Card (no coverage): Reduces cash price to roughly $550 per month for eligible patients without insurance coverage for Zepbound.
• LillyDirect: Lilly's direct-to-patient platform offers Zepbound vials (not pens) at $349 to $499 per month for cash-pay patients on the 2.5 mg and 5 mg doses.

Mounjaro has similar programs but is restricted to patients with type 2 diabetes, not weight management.

The fine print that trips people up:

• Savings cards are not valid for Medicare, Medicaid, or other federal programs
• The lowest copay requires commercial insurance, which you may or may not have
• Annual savings are capped (typically $1,800 to $3,600 per year)
• Programs can be discontinued or restructured at any time, and Lilly has done both

The Insurance Coverage Gap Nobody Warns You About

Insurance coverage for tirzepatide is split down the middle in a way that can feel almost cruel.

For type 2 diabetes (Mounjaro): Most commercial plans cover it with prior authorization. Medicare Part D covers Mounjaro for FDA-approved indications. If you have a confirmed type 2 diabetes diagnosis, coverage is generally accessible.

For weight management (Zepbound): A different world. Many commercial plans exclude weight management medications as an entire benefit class. Medicare does not cover weight management drugs by statute. Employer plans vary wildly and often stack requirements: BMI threshold (typically 35 or higher), documented participation in a weight management program, and prior authorization.

The practical result: a patient with type 2 diabetes can probably get Mounjaro covered. A patient with obesity but no diabetes diagnosis is almost certainly facing a cash-pay decision. This is the coverage gap that sends people like Rachel into CVS parking lots doing mental math.

Our supporting article on insurance coverage for tirzepatide covers the prior authorization process and appeals strategies in depth.

Compounded Tirzepatide: Where the Price Drops

Compounded tirzepatide is dispensed by 503A pharmacies (state-licensed compounding pharmacies preparing individual prescriptions) and 503B outsourcing facilities (FDA-registered facilities producing larger batches).

Prices vary by pharmacy, dose, and how much markup sits between you and the pharmacy. Typical ranges in 2025:

• 2.5 mg per week: $150 to $250 per month
• 5 mg per week: $200 to $350 per month
• 7.5 mg per week: $250 to $400 per month
• 10 mg per week: $300 to $500 per month
• 12.5 mg per week: $350 to $550 per month
• 15 mg per week: $400 to $600 per month

Those wide ranges reflect provider markup. A telehealth platform might charge $500 per month for a dose that the pharmacy itself would charge $250 for, with the difference covering clinical consultation, prescription writing, and platform overhead.

The cheapest path? Direct-to-pharmacy pricing, where you bring a prescription from your own doctor. But that requires an established prescribing relationship, which not everyone has.

Why the price is lower: Brand drug prices bake in R&D recoupment, direct-to-consumer advertising, sales forces, patent premiums, and manufacturer margins. Compounded products skip all of that. The cost structure is the active pharmaceutical ingredient (tirzepatide itself, sourced from suppliers), plus formulation labor, regulatory compliance overhead, and pharmacy margin.

That said, "cheaper" doesn't mean "identical." Compounded tirzepatide is not FDA-approved. It is not therapeutically equivalent to Mounjaro or Zepbound in the regulatory sense. The molecule is the same; the finished product is not. This is a distinction that matters, and anyone selling compounded tirzepatide who glosses over it deserves skepticism.

The supporting article on why compounded tirzepatide is cheaper explains the supply chain economics in detail.

A Year of Tirzepatide: The Numbers That Actually Matter

Nobody makes this decision one month at a time. The real question is what a year costs, because tirzepatide isn't a course of antibiotics. It works while you take it.

• Brand cash pay: roughly $12,828 per year
• Zepbound Savings Card + commercial insurance: as low as $300 per year (subject to annual caps)
• Zepbound Savings Card, no coverage: roughly $6,600 per year
• LillyDirect vials at $349/month (5 mg): roughly $4,188 per year (only available at lower doses)
• Compounded, direct-to-pharmacy at $250/month average: roughly $3,000 per year
• Compounded via telehealth at $400/month average: roughly $4,800 per year

The story these numbers tell is stark. If you have commercial insurance that covers Zepbound and you qualify for the savings card, you're looking at hundreds per year. If you're paying cash for brand, you're looking at a used car. Compounded tirzepatide and LillyDirect occupy the middle ground, and for many people, that middle ground is the difference between staying on therapy and stopping.

Here's my genuinely held opinion: the single biggest policy failure in obesity medicine right now isn't the FDA approval process or the compounding debate. It's that Medicare, by statute, cannot cover weight management drugs. Until that changes, millions of patients over 65 are locked out of medications that work, full stop.

Quality Red Flags and Minimum Standards

Price is a necessary input to the decision, but buying the cheapest thing you can find and injecting it is not a risk-reward calculation any rational person should accept. When evaluating compounded tirzepatide providers, look for:

• The pharmacy is licensed in your state and identifiable by name (not hidden behind a brand)
• The pharmacy publishes its DEA, state license, and (if applicable) 503B registration
• The product is tested for sterility, potency, and endotoxins by an accredited third-party lab
• Certificates of analysis are available upon request
• The prescribing clinician is licensed in your state

Think of these like checking that a restaurant has a health inspection grade posted. Their presence doesn't guarantee an amazing meal, but their absence should make you walk out.

The supporting article on evaluating compounded tirzepatide providers covers the full diligence checklist.

Note: Same active ingredient does not mean identical product. Compounded tirzepatide is not FDA-approved and is not therapeutically equivalent to Mounjaro or Zepbound in the regulatory sense.

Telehealth, State Rules, and the Regulatory Quicksand

Telehealth has made compounded tirzepatide widely accessible, but the regulatory terrain is state-specific and shifting fast. A telehealth provider must be licensed in the state where the patient is physically located. A 503A compounding pharmacy must be licensed to ship into your state.

Some states have additional restrictions on compounded GLP-1 products. Florida, California, and a handful of others have proposed or enacted rules affecting what 503A pharmacies can compound. If your provider and pharmacy haven't confirmed compliance in your state, that's a problem.

The FDA placed tirzepatide on the official shortage list from 2022 to 2024, which provided the legal basis under FDA guidance for 503A pharmacies to compound it. The shortage was officially resolved in late 2024, with FDA giving compounders a wind-down window before enforcement.

The practical landscape keeps evolving. Some 503A pharmacies have stopped compounding tirzepatide. Some 503B outsourcing facilities continue under different regulatory pathways. Some providers have pivoted to compounding tirzepatide with B12 or other additives, which raises a separate set of legal questions.

The boring truth: if you're on compounded tirzepatide, you should plan for the possibility that your current source may disappear. Talk to your clinician now about what the transition path would look like, not after the pharmacy sends you a "we're no longer able to fill" email.

The supporting article on tirzepatide compounding regulations covers the regulatory landscape in more depth.

Supporting Articles in This Cluster

This hub anchors a cluster of supporting articles covering every aspect of tirzepatide cost and access:

1. Tirzepatide Cash Price Comparison
2. Tirzepatide Insurance Coverage and Prior Auth
3. Why Compounded Tirzepatide Is Cheaper
4. Evaluating Compounding Pharmacies
5. Tirzepatide Compounding Regulations
6. LillyDirect: What It Is and Who Qualifies
7. Zepbound Savings Card Eligibility
8. Tirzepatide and HSA/FSA Coverage
9. International Tirzepatide Pricing
10. How to Switch from Brand to Compounded

Frequently Asked Questions

1. Why is GoodRx not cheaper for tirzepatide?

Tirzepatide is a single-source brand drug with no generic equivalent. GoodRx negotiates discounts from already-tight pharmacy margins on brand drugs. Without generic competition, the available discount is small, typically 3 to 10 percent.

2. Does insurance ever cover Zepbound?

Yes, but coverage is restrictive. Many commercial plans exclude weight management drugs entirely. Plans that do cover Zepbound typically require BMI thresholds, prior authorization, and documented weight loss attempts.

3. Why does compounded tirzepatide cost less than brand?

Compounded products skip the R&D recoupment, marketing, sales force, and patent premium costs built into brand drug pricing. The active ingredient cost plus formulation labor plus pharmacy margin is structurally lower.

4. Is compounded tirzepatide the same as Mounjaro or Zepbound?

The active pharmaceutical ingredient is the same molecule. The finished product is not the same. Compounded tirzepatide is not FDA-approved and is not therapeutically equivalent in the regulatory sense.

5. What is LillyDirect?

LillyDirect is Eli Lilly's direct-to-patient platform that offers Zepbound vials (not pens) at reduced cash-pay prices. As of late 2025, prices started at $349 per month for the lower doses.

6. Will my HSA or FSA cover tirzepatide?

Yes, if it is prescribed by a licensed clinician for an FDA-approved indication or for medically appropriate off-label use. Compounded tirzepatide is typically HSA-eligible with a valid prescription.

7. Can I import tirzepatide from another country?

Personal importation of prescription drugs is generally not permitted under FDA rules. Enforcement varies, but it is not a recommended path due to quality, legal, and supply continuity concerns.

8. How much does a year of tirzepatide cost out of pocket?

Brand cash pay: roughly $12,800. With Zepbound Savings Card and no insurance: roughly $6,600. LillyDirect at low doses: roughly $4,200. Compounded direct-to-pharmacy: roughly $3,000. Compounded telehealth: roughly $4,800.

9. What happens if my compounded tirzepatide source shuts down?

You'll need to transition to either brand product (Mounjaro or Zepbound), a different compounding source, or a different GLP-1 medication. Discuss the transition plan with your clinician before you face an interruption.

10. Are there ever payment plans for tirzepatide?

Some telehealth providers offer monthly payment plans. Some compounding pharmacies offer prepaid multi-month discounts. Brand manufacturer programs cap savings per year rather than offering financing.

---

Disclaimer: This article is for informational purposes only and is not medical advice. Compounded tirzepatide is not FDA-approved. FormBlends is not a medical practice and does not prescribe or dispense medication. All prices are estimates and subject to change.

Return to the Compounded Tirzepatide Complete Guide.